Study Highlights Challenge of Selecting Patients for Mesothelioma Immunotherapy – Surviving Mesothelioma
Surviving Mesothelioma |
Study Highlights Challenge of Selecting Patients for Mesothelioma Immunotherapy
Surviving Mesothelioma A new study is casting some doubt on the value of a protein called PD-L1 as a way to select mesothelioma patients for targeted immunotherapy. Several of the most promising new treatments for malignant mesothelioma, including pembrolizumab (Keytruda) … |
